NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMSHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
NAMS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.59B
- EPS (TTM)
- -$2.16
- Dividend yield
- None
- 52-week range
- 21.02 – 42.21
- Day range
- 21.85 – 22.72
- Volume / Avg
- 1.38M / 1.35M
- Beta
- —
- Shares outstanding
- 116.90M
- Next earnings
- Nov 4, 2026
52-week range
NAMS stock today
NewAmsterdam Pharma N.V. (NAMS) closed at $22.13 on Oct 7, down 0.63% (-$0.14), versus the S&P 500's 0.22% decline. Shares are 47.6% below their 52-week high of $42.21, set on May 11, 2026 and 5.3% above the 52-week low of $21.02, near the bottom of the past year's range. NAMS is down 36.9% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 31.3%.
NewAmsterdam Pharma N.V. has posted a net loss over the last twelve months (EPS of -$2.16), so its P/E ratio is not meaningful. NewAmsterdam Pharma N.V.'s next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About NewAmsterdam Pharma N.V.
Company profileNewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Michael Harvey Davidson FACC, Facp., M.D.
- Headquarters
- Naarden
- Employees
- 100
- Website
- newamsterdampharma.com
Financial highlights
Full financialsIn fiscal 2025, NewAmsterdam Pharma N.V. generated $22.5 million in revenue, down 50.6% from fiscal 2024, its first annual decline since 2023. NewAmsterdam Pharma N.V. reported a net loss of $203.8 million, compared with a loss of $241.6 million a year earlier. Operating margin was -1002.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $22.50M | $45.56M | $14.09M | $102.69M | — |
| Growth | -50.61% | +223.37% | -86.28% | — | — |
| Net income | $-203.82M | $-241.60M | $-176.94M | $-22.63M | $-41.78M |
| EPS (diluted) | $-1.72 | $-2.56 | $-2.15 | $-1.19 | $-3.81 |
Analyst forecast
ForecastConsensus (16 analysts)
strong_buy
Avg. price target
$49.65+124.36%
- Strong buy 3
- Buy 12
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $-0.50
- Last reported (Q2 2026)
- Aug 5, 2026
- EPS actual vs est.
- $-0.52 vs —
NewAmsterdam Pharma N.V. peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MBXMBX Biosciences Inc. | 54.54 | -4.18% | $2.63B | vs NAMS |
| AUPHAurinia Pharmaceuticals Inc | 16.01 | +2.04% | $2.13B | vs NAMS |
| DNLIDenali Therapeutics Inc. | 19.16 | -0.62% | $3.06B | vs NAMS |
| URGNUroGen Pharma Ltd. | 40.70 | -1.76% | $1.99B | vs NAMS |
| TRVITrevi Therapeutics Inc. | 13.14 | -0.30% | $1.87B | vs NAMS |
| ADRXADARx Pharmaceuticals Inc. | 17.33 | -6.73% | $1.85B | vs NAMS |
| NVAXNovavax Inc. | 11.22 | -0.88% | $1.85B | vs NAMS |
| STOKStoke Therapeutics Inc. | 24.29 | -0.33% | $1.57B | vs NAMS |
Indexes, lists and sector
Appears in lists
NewAmsterdam Pharma N.V. stock FAQ
What is NewAmsterdam Pharma N.V.'s stock price today?
NAMS last traded at $22.13 as of Oct 7, 4:00 PM EDT, down 0.63% on the day. Prices are delayed at least 15 minutes.
When is NewAmsterdam Pharma N.V.'s next earnings date?
NewAmsterdam Pharma N.V. is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $-0.50.
Who is NewAmsterdam Pharma N.V.'s CEO?
Dr. Michael Harvey Davidson FACC, Facp., M.D. is the chief executive officer of NewAmsterdam Pharma Company N.V., which has about 100 employees.
What is the NAMS 52-week high?
The 52-week high for NAMS is $42.21 and the 52-week low is $21.02. The stock is currently 47.6% below its high.